Parkinson’s disease therapy

Oct 09, 2026

Summary On September 28, 2026, the FDA approved AbbVie’s JUVMO (tavapadon) as the first selective dopamine D1/D5 receptor agonist for adults with Parkinson’s disease, introducing a new dopaminergic approach after decades dominated by levodopa and D2/D3 agonists. The approval was supported by findings from the T...

Nov 18, 2024

Parkinson’s disease is the second most common neurodegenerative disorder after Alzheimer’s disease. It affects about 10 million people worldwide. The average age of onset for Parkinson’s disease is around 60; however, approximately 10-15% of patients experience early-onset PD before the age of 50. In 2023, there...